Reuters logo
BRIEF-FDA accepts Prometic's Biologics License Application for Plasminogen
October 13, 2017 / 10:38 AM / 2 months ago

BRIEF-FDA accepts Prometic's Biologics License Application for Plasminogen

Oct 13 (Reuters) - Prometic Life Sciences Inc

* Prometic announces FDA acceptance of its Biologics License Application for Plasminogen (Ryplazim™)

* Prometic Life Sciences Inc - ‍prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below